docetaxel, carboplatin, and rucaparib camsylate
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for docetaxel, carboplatin, and rucaparib camsylate, covering 2026-08-26 to 2026-08-26. Get the full timeline:
Most recent: Clinical Trial Results: Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency [Phase 2]